Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Multiple Sclerosis Centers of Excellence


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Natalizumab (Tysabri®)

Natalizumab (Tysabri®) is a humanized monoclonal antibody directed at alpha 4 beta 1 integrin, a lymphocyte cell surface receptor involved in cell adhesion. It is thought to act in MS by limiting the migration of lymphocytes across the blood brain barrier, thereby reducing demyelination and inflammation in the brain or spinal cord. It was found to have a dramatic effect on MS disease activity to reduce the frequency of exacerbations. The recommended dose of natalizumab for relapsing forms of MS is 300 mg by IV infusion over one hour every four weeks. Side effects include urticaria and flushing.

Patients must have a JC virus test prior to initiation of natalizumab, due to the risk of developing progressive multifocal leukoencephalopathy (PML) caused by the JC polyomavirus. Patients on natalizumab should be evaluated at 3 months and 6 months after the first infusion and at least every 6 months after that for clinical response, side effects, and any symptoms suggesting PML as well as a decision to continue natalizumab therapy.

The medication must be prescribed through the Tysabri Outreach: Unified Commitment to Health (TOUCH™) program. Individuals who have questions about natalizumab should contact their healthcare provider.

For More Information

Natalizumab (Tysabri®) Monograph
Natalizumab (Tysabri®) Criteria for Use 
VA Adverse Drug Events Reporting System 
Tysabri® (website for patients and professionals)